2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

Similar documents
988 CHEMOTHERAPY NOV. 1971

Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX


CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY

VOL. 34 S-2 CHEMOTH8RAPY 913

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis



CHEMOTHERAPY FEB Table 1 Background of volunteers

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL.42 S-1

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates


CHEMOTHERAPY MAY. 1988

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY JUNE 1986


CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk


CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

Table1MIC of BAY o 9867 against standard strains


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone


Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.


VOL.39 S-3


CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY


CHEMOTHERAPY JUNE 1988 ( })-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-l-piperaziny1) 4-oxo-3-quinolinecarboxylic acid hydrochloride Fig. 1. Chemica

CHEMOTHERAPY



CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle


A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc

Fig. 1 Chemical structure of norfioxacin (AM-715)


CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

日本化学療法学会雑誌第53巻第S-3号

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL



CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

CHEMOTHERAPY APR. 1982

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -



Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

Transcription:

2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1

VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table 3 Susceptibility distribution of E. coli to aminoglycosides (54 strains)

2110 CHEMOTHERAPY SEPT. 1977 Table 4 Susceptibility distribution of Proteus sp. to aminoglycosides (27 strains) Table 5 Susceptibility distribution of Klebsiella to aminoglycosides (27 strains) Table 6 Susceptibility distribution of Pseudomonas aeruginosa to aminoglycosides (54 strains)

VOL. 25 NO. 7 CH5MOTHERAPY 2111 Table 7 Serum levels of KW-1062 (40 mg i. m.) Fig. 2 Cross resistance (Pseudomonas aeruginosa 54 strains) Fig. 4 Standard curve of KW-1062 Fig. 3 Cross resistance (Pseudomonas aeruginosa 54 strains) Fig. 5 Serum level of KW-1062 (40 mg i. m. ) Test org.: B. subtilis. ATCC 6633 Medium : HIA, 5ml single laver Method : paper disc method Standard curve : using Moni -trol I serum

CHEMOTHERAPY SEPT. 1977 Table 8 Urinary excretions of KW-1062 (40 mg i. m.) Table 9 Tissue concentrations of KW-1062 Fig. 6 Urinary excretion of KW-1062 (40mg i.m.) Fig. 7 Tissue concentration of KW-1062 (20 mg/kg i. m. )

VOL. 25 NO. 7 CHEMOTHERAPY 2113 Fig. 8 Bioautogram of KW-1062 Solvent : CHCl3: MeOH: NH4OH : H2O= 1 : 4 : 2 : 1 Adsorbent : Spotfilm (Tokyo Kasei) Test org. : B. subtilis ATCC 6633

2114 CHEMOTHERAPY SEPT. 1977 Fig. 9 T. N. 59 yrs male, Haemopyothorax (rupture of herniated colon through traumatic fissure of diaphragma) Fig. 10 K. T. 47 yrs male, Local peritonitis after gastrectomy (B- II) (perforative duodenal ulcer) Fig. 11 T. M. 51 yrs male, Post-op. intra-abdominal abscess (gallstone with cholecystitis)

VOL. 25 NO. 7 CHEMOTHERAPY 2115 5) ISHIYAMA, S. ; I. NAKAYAMA, H. IWAMOTO, S. IWAI, I. MURATA & M. OHASHI : Clinical use of tobramycin in patients with surgical infection due to gram-negative bacilli. J. Infect. Diseases 134 (Suppl. ) : 178 `481 August, 1976 STUDIES ON KW-1062 IN SURGERY-ANTIBACTERIAL ACTIVITIES, ABSORPTION, EXCRETION, METABOLISM AND CLINICAL APPLICATION TAKASHI SAKABE, ISSEI NAKAYAMA, HIDEO IWAMOTO, SHIGETOMI IWAI, MUTSUMI TAKATORI, TAKAMICHI KAWABE, MITSURU OHASHI, IKUO MURATA, HIROAKI SUGIYAMA and YUKO MIZUASHI Third Department of Surgery, Nihon University, School of Medicine SHUNJI ISHIYAMA Research Institute of Sciences, Nihon University 1. KW-1062, a new aminoglycoside antibiotic, was studied on antibacterial activities, absorption, excretion, metabolism and clinical application. 2. KW-1062 has a broad antibacterial spectrum against gram-positive and gram-negative bacteria, which is similar to that of gentamicin (GM). 3. The susceptibility of KW-1062 against clinically isolated strains from surgical focuses was determined, and the following results were obtained. Antibacterial activity of KW-1062 against Staph. aureus was similar to that of GM and tobramycin (TUB), and regarding the activity against E. coli, KW-1062 was similar to dibekacin and a little less than GM. The activity of KW-1062 against Proteus sp. was similar to that of GM, and against Klebsiella, it was almost equal to that of TUB and less than that of GM. Against Pseudomonas aeruginosa, KW-1062 was as active as GM. 4. Three: healthy adults were administered 40 mg of KW-1062 intramuscularly, and 30 minutes after dosing the serum level reached the peak, 2. 47 Đg/ml. Urinary recovery of KW-1062 during 6 hours in these cases was 75. 8% on an average.

2116 CHEMOTHERAPY SEPT. 1977 5. Tissue level of KW-1062 in rats was highest in the kidney and serum, but it was not detectable in the liver. 6. Bioautogram of the urine collected from healthy adults having intramuscular administration of 40 mg of KW-1062 showed no metabolites with antibacterial activity except KW-1062 itself. 7. Clinical response to KW-1062 in surgical infectious diseases was good in 4 cases, fair in 1 case and poor in 2 cases. A dose of KW-1062 was 40-80 mg/time. It appeared effective when intramuscular injection at this dose was given three times/day. 8. As a side effect, the elevation of GOT and GPT was observed in 1 case, but it was unknown if the elevation was due to KW-1062, because of combination with another antibiotic agent. Side effect which may have been caused by KW-1062 was not observed, including of this case.

2026 © docsplayer.net プライバシー | 利用規約 | フィードバック